You just read:

Nordic Nanovector Announces First Patient Dosed in Phase 1 Study of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL), an Aggressive Form of NHL

News provided by

Nordic Nanovector

Mar 17, 2017, 02:10 ET